Latest Neulasta news
FDA OKs 1st Biosimilar to Prevent Chemo-Related Infections
posted June 5th
by modernClinician Editorial Team
by modernClinician Editorial Team
The first biosimilar drug to Neulasta has been approved by the U.S. Food and Drug Administration. Fulphila (pegfilgrastim) is approved for patients with non-myeloid cancer who are receiving myelosuppressive chemotherapy and have symptoms of febrile neutropenia.
Most Speakers at FDA Advisory Committee Meetings Support Drug Approval 
Countries Involved in U.S. Clinical Trials Do Not Gain Timely Access to Approved Medicines 
FDA Suspends U.S. License of Chikungunya Vaccine Related Articles
4CMenB Vaccine Confers Modest Protection Against Gonorrhea in Teens 
AAP Releases Influenza Vaccine Recommendations for All Children 6 Months and Older 
Adverse Event Risk Not Up With Same Day COVID-19, Flu Vaccination Monthly Specialist Briefings
Stay Connected
